ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 ...
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...
Morgan Stanley sets Novo Nordisk stock at Equalweight
Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...
Novo Nordisk A/S (NVO): Among the Best International Dividend Stocks to Buy Now
We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...